Hepatitis E and blood donation safety in selected European countries: a shift to screening?

Autor:	Domanović D; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Tedder R; Hepatitis E Study Group, Joint PHE/NHSBT Blood Borne Virus Unit, PHE, Colindale, London, United Kingdom., Blümel J; Paul-Ehrlich-Institute, Federal Institute for Vaccines and Biomedicines, Virus Safety Section, Langen, Germany., Zaaijer H; Sanquin, Blood-borne Infections & AMC, Clinical Virology, Amsterdam, the Netherlands., Gallian P; Etablissement Français du Sang, Saint-Denis, France., Niederhauser C; Interregionale Blood Transfusion SRC, Berne, Switzerland., Sauleda Oliveras S; Transfusion Safety Laboratory, Banc de Sang i Teixits, Barcelona, Catalonia, Spain., O'Riordan J; Irish Blood Transfusion Service, Dublin, Ireland., Boland F; Irish Blood Transfusion Service, Dublin, Ireland., Harritshøj L; Rigshospitalet, Department of Clinical Immunology, Copenhagen, Denmark., Nascimento MSJ; University of Porto, Faculty of Pharmacy, Porto, Portugal., Ciccaglione AR; National Health Institute, Viral Hepatitis Division, Department of Infectious Diseases, Rome, Italy., Politis C; Hellenic Coordinating Haemovigilance Centre, Athens, Greece., Adlhoch C; European Centre for Disease Prevention and Control (ECDC), Stockholm, Sweden., Flan B; LFB Biomedicaments, Biological Safety Surveillance, Courtaboeuf Cedex, France., Oualikene-Gonin W; Agence nationale de sécurité du médicament et des produits de santé, Saint-Denis Cedex, France., Rautmann G; European Directorate for the Quality of Medicines and HealthCare, Strasbourg, France., Strengers P; International Plasma Fractionation Association, Amsterdam, Netherlands., Hewitt P; NHS Blood and Transplant, London, United Kingdom.
Jazyk:	angličtina
Zdroj:	Euro surveillance : bulletin Europeen sur les maladies transmissibles = European communicable disease bulletin [Euro Surveill] 2017 Apr 20; Vol. 22 (16).
DOI:	10.2807/1560-7917.ES.2017.22.16.30514
Abstrakt:	The public health implications of hepatitis E virus (HEV) in Europe have changed due to increasing numbers of hepatitis E cases and recent reports of chronic, persistent HEV infections associated with progression to cirrhosis in immunosuppressed patients. The main infectious risk for such immunosuppressed patients is exposure to undercooked infected pork products and blood transfusion. We summarised the epidemiology of HEV infections among blood donors and also outlined any strategies to prevent transfusion-transmitted HEV, in 11 European countries. In response to the threat posed by HEV and related public and political concerns, most of the observed countries determined seroprevalence of HEV in donors and presence of HEV RNA in blood donations. France, Germany, Spain and the United Kingdom (UK) reported cases of transfusion-transmitted HEV. Ireland and the UK have already implemented HEV RNA screening of blood donations; the Netherlands will start in 2017. Germany and France perform screening for HEV RNA in several blood establishments or plasma donations intended for use in high-risk patients respectively and, with Switzerland, are considering implementing selective or universal screening nationwide. In Greece, Portugal, Italy and Spain, the blood authorities are evaluating the situation. Denmark decided not to implement the HEV screening of blood donations. (This article is copyright of The Authors, 2017.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu